ArticleMicrobiology spectrum2022
Activity of
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- N-acetylcysteine as an adjunct to antibiotics against bacterial biofilms: A systematic review of in vitro evidence.Biofilm · 2026Review
- Review
- Establishment and application of a vesicle extraction method for clinical strains ofMicrobiology spectrum · 2026Article
- Repurposing Non-Infectious Therapeutic Agents to Aid in the Treatment of Chronic Biofilm Infections.Medical sciences (Basel, Switzerland) · 2026Review
- Combating biofilm formation and bacterial killing: N-acetylcysteine's efficacy againstBiofilm · 2025Article
- N-acetylcysteine inhibits NETs, exhibits antibacterial and antibiofilm properties and enhances neutrophil function against Burkholderia pseudomallei.Scientific reports · 2025Article
- Synergistic action of mucoactive drugs and phages againstMicrobiology spectrum · 2025Article
- N-acetyl cysteine as an additive to bone cement against pathogens involved in periprosthetic joint infections.Frontiers in bioengineering and biotechnology · 2025Article
- Intrinsic antimicrobial resistance: Molecular biomaterials to combat microbial biofilms and bacterial persisters.Biomaterials · 2024Review
- Analysis of the utility of a rapid vesicle isolation method for clinical strains ofMicrobiology spectrum · 2024Article
- Article
- The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Acetylcysteine increases sensitivity of ceftazidime-avibactam-resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo.BMC microbiology · 2023Article
- Advances in the Use ofAntioxidants (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic colonization by Pseudomonas aeruginosa is critical in cystic fibrosis (CF) and other chronic lung diseases, contributing to disease progression. Biofilm growth and a propensity to evolve multidrug resistance phenotypes drastically limit the available therapeutic options. In this perspective, there has been growing interest in evaluating combination therapies, especially for drugs that can be administered by nebulization, which allows high drug concentrations to be reached at the site of infections while limiting systemic toxicity. Here, we investigated the potential antibiofilm activity of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.